Mammary Cell News Volume 15.43 | Nov 2 2023

    By
    Bob
    -
    0
    11








    2023-11-02 | MCN 15.43


    Mammary Cell News by STEMCELL Technologies
    Vol. 15.43 – 2 November, 2023
    TOP STORY

    Toxic PARP Trapping upon cAMP-Induced DNA Damage Reinstates the Efficacy of Endocrine Therapy and CDK4/6 Inhibitors in Treatment-Refractory ER+ Breast Cancer

    Scientists showed that standard-of-care therapy caused DNA damage and toxic PARP1 trapping upon generation of a functional BRCAness phenotype, leading to increased histone parylation and reduced H3K9 acetylation, resulting in transcriptional blockage and cell death.
    [Nature Communications]

    Full ArticlePress Release
    As a scientist, how you separate the facts from the claims is just as important as how you separate your cells. See for yourself.
    PUBLICATIONSRanked by the impact factor of the journal

    Luminal Breast Cancer Identity Is Determined by Loss of Glucocorticoid Receptor Activity

    Researchers utilized an in silico-designed glucocorticoid receptor (GR) activity signature to demonstrate that GR related to the proliferative capacity of numerous primary cancer types.
    [EMBO Molecular Medicine]

    Full ArticleGraphical Abstract

    Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer

    The authors found metabolic reprogramming that increased fatty acid β-oxidation in estrogen receptor-alpha positive breast cancers as a mechanism of resistance to endocrine therapy.
    [Cancer Research]

    Abstract

    RCCD1 Promotes Breast Carcinogenesis through Regulating Hypoxia-Associated Mitochondrial Homeostasis

    Researchers revealed an additional dimension of regulator of chromosome condensation domain-containing protein 1 (RCCD1) functionality in regulating mitochondrial homeostasis, whose dysregulation inflicted pathologic states such as breast cancer.
    [Oncogene]

    Abstract

    Indacaterol Inhibits Collective Cell Migration and IGDQ-Mediated Single Cell Migration in Metastatic Breast Cancer MDA-MB-231 Cells

    The authors characterized the migratory phenotype of MDA-MB-231 cells, using functionalized IGDQ-exposing surfaces, and compared it to integrin A5 and integrin B3 knock-down cells.
    [Cell Communication and Signaling]

    Full Article

    Cellular Context Dictates the Suppression or Augmentation of Triple-Negative Mammary Tumor Metastasis by NLRX1

    Scientists explored the role of NLRX1 in the highly metastatic murine 4T1 mammary tumor model. They demonstrated that NLRX1 functions as a tumor suppressor when expressed in the host cells.
    [Journal of Immunology]

    Abstract

    Targeting the ZNF-148/miR-335/SOD2 Signaling Cascade Triggers Oxidative Stress-Mediated Pyroptosis and Suppresses Breast Cancer Progression

    Knockdown of zinc finger protein 148 (ZNF-148) suppressed malignant phenotypes, including cell proliferation, epithelial-mesenchymal transition, and tumorigenesis in vitro and in vivo, while ZNF-148 overexpression had the opposite effects.
    [Cancer Medicine]

    Full Article

    Ceramide Synthase 4 Overexpression Exerts Oncogenic Properties in Breast Cancer

    The molecular effects of long-term ceramide synthase 4 (CerS4) overexpression on breast cancer progression and migration were explored using TCGA-BRCA data, MCF-7 cells stably overexpressing CerS4, and doxorubicin-resistant MCF-7 cells.
    [Lipids in Health and Disease]

    Full Article

    Ezetimibe Inhibits Triple-Negative Breast Cancer Proliferation and Promotes Cell Cycle Arrest by Targeting the PDGFR/AKT Pathway

    Investigators demonstrated that Ezetimibe inhibited the PDGFR/AKT pathway, thereby halting TNBC cycle progression and tumor growth.
    [Heliyon]

    Full Article
    Explore the Science Events Calendar to discover conferences, podcasts, webinars, and more!
    REVIEWS

    Progress in the Understanding of Estrogen Receptor Alpha Signaling in Triple-Negative Breast Cancer: Reactivation of Silenced ER-α and Signaling through ER-α36

    The reactivation of estrogen receptor alpha (ER-α), presents a potential strategy to re-sensitize TNBC to hormonal therapy. Scientists provide up-to-date information related to the direct involvement of miRNA in regulating the translation of ER-α mRNA.
    [Molecular Cancer Research]

    Abstract
    INDUSTRY AND POLICY NEWS

    Open-Access Reformers Launch Next Bold Publishing Plan

    The group behind the radical open-access initiative Plan S has announced its next big plan to shake up research publishing — and this one could be bolder than the first. It wants all versions of an article and its associated peer-review reports to be published openly from the outset, without authors paying any fees.
    [Nature News]

    Press Release
    FEATURED EVENT

    Cell & Gene Therapy Manufacturing & Commercialization Europe

    December 4 – 7, 2023
    Dublin, Ireland

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Associate – Breast Cancer Metastases

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Researcher – Breast Cancer Program

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    Postdoctoral Associate – Translational Oncology

    Baylor College of Medicine – Houston, Texas, United States

    PhD Positions – Cancer Mechanobiology

    University of Galway – Galway, Ireland

    Clinical Research Associate – Breast

    Cedars-Sinai – Los Angeles, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Logo for the social media website X